For Healthcare Professionals

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma


About the study

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. 18 years or older at the time of signing the ICF.
  2. Body weight > 35 kg.
  3. Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
  4. Has measurable target disease assessed by the Investigator based on RECIST 1.1.
  5. ECOG PS zero or one.
  6. Life expectancy of at least 12 weeks.
  7. Adequate organ and bone marrow function.
  8. Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.


Exclusion Criteria:

  1. Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
  2. Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
  3. Participants with ascites which cannot be controlled with appropriate interventions.
  4. Active infectious diseases, including tuberculosis, HIV infection, or hepatitis B/C.
  5. Uncontrolled intercurrent illness.
  6. Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
  7. History of another primary malignancy.
  8. Previous treatment with an immune-oncology agent.
  9. Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Gastric Cancer

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Mar 31, 2026

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.